60). PPH was observed in 7/24 (29%) deliveries in women known prepregnancy to have VWD. The unadjusted odds for VWD as a risk factor for PPH in this group was significantly greater than the control group (OR 2.78 (95% CI 1.03–7.49) P = 0.043) and remained significant after adjusting for other significant risk factors (OR 3.41 (95% CI 1.07–10.9) P = 0.038). VWD in itself may not be a significant risk factor for PPH, however, women known to have VWD predelivery may represent an at risk sub-group. “
“The development of inhibitors usually renders hemophilia A patients refractory to factor VIII replacement therapy. The inhibitor bypassing agents

activated PCC and recombinant activated factor VII (rFVIIa) are highly effective for Sorafenib datasheet treating bleeding and for providing surgical hemostasis but responses Sunitinib clinical trial are not entirely predictable, and they cannot be monitored by conventional laboratory assays. Their high cost may make them relatively inaccessible in developing countries. Eradication of inhibitors by induction of immune tolerance (ITI) is achievable in most patients but there is no consensus on optimal regimens. Promising new agents for inhibitor treatment are under development, including recombinant porcine factor VIII and altered rFVIIa molecules with enhanced potency or improved pharmacokinetics. Factor IX inhibitors in hemophilia B patients occur rarely but

they are even more problematic, as they may be associated with severe allergic reactions and they respond poorly to ITI. “
“Summary.  Previous data have shown an inter-individual difference in the thrombin check details generating capacity in vitro as well as phenotypic bleeding pattern among patients with severe haemophilia A (FVIII:C activity below 1%). The reason for this is not

known. In addition, there are no reports on how thrombin generation may correlate between siblings. In this study, we evaluated and compared thrombin generation in vitro using plasma samples in the presence of by-passing agents (FEIBA® and NovoSeven®) in 21 unrelated brother pairs with and without inhibitors enrolled in the Malmö International Brother Study (MIBS). Mean maximum thrombin formation in patients with a current inhibitor titer was 182.0 ± 52.8 mmol mL−1 (FEIBA®) and 130.7 ± 54.9 mmol mL−1 (rFVIIa), respectively, and somewhat higher in those without inhibitors, 222.7 ±85.5 mmol mL−1 (FEIBA®) and 142.8 ±53.6mmol mL−1 (rFVIIa) (P = 0.16 and 0.29). The variance regarding the maximum thrombin production within a family was significantly lower compared with the thrombin production between families (P < 0.001 for both FEIBA® and NovoSeven®). Our data indicate that genetically determined factors, other than the FVIII:C activity seems to influence the phenotypic variation in thrombin formation in the presence of by-passing agents. The nature of these determinants remains to be identified.